Latest Regulatory News

Tamboran Resources is set to acquire Falcon Oil & Gas, creating a dominant player with approximately 2.9 million net prospective acres in Australia's Beetaloo Basin. The deal, valued at over US$500 million pro forma, aims to strengthen Tamboran's development footprint and shareholder base.

Australia and New Zealand Banking Group Limited (ANZ) has announced a quarterly distribution of AUD 1.2556 per security on its capital notes, with a 70% franking rate and payment scheduled for December 22, 2025.

OzAurum Resources has launched a targeted drilling campaign at its Mulgabbie North Gold Project, aiming to expand high-grade zones and advance feasibility studies amid record gold prices.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

Aguia Resources has announced a one-for-ten entitlement issue to raise up to $4 million, including free attaching options, aimed at advancing its Santa Barbara Gold Project and supporting working capital.

360 Capital Mortgage REIT (ASX – TCF) has announced an off-market equal access buy-back of up to 5% of its units, offering eligible unitholders a chance to sell at a price linked to net tangible asset backing plus distributions. The buy-back opens on 8 October 2025 and closes on 27 October 2025.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

Sprintex Limited has raised $1.5 million through a strategic placement to advance its ammonia-reduction technology in Europe, supported by pending orders worth €9.3 million. The funding underscores growing investor confidence amid tightening environmental regulations.